BioSpace News Archive

P ublic Health Agency of Canada Contract would be Second Contract by a Canadian Governmental Agency for the Procurement of Oral TPOXX Delivery of 18,500 Courses by March 31, 2023; Delivery of Additional 14,800 Courses Subject to Option Exercise NEW YORK, Oct. 08, 2020 (GLOBE NEWSWIRE) -- SIGA Technologies, Inc. (SIGA) (NASDAQ: SIGA), a commercial-stage pharmaceutical company focused on the health security market, today announced that the Public Health Agency of Canada

Helius Medical Technologies, Inc. (NASDAQ:HSDT) (TSX:HSM) (“Helius” or the “Company”), a neurotech company focused on neurological wellness, today announced the formation of a Multiple Sclerosis (“MS”) Scientific Advisory Board. The Helius MS Scientific Advisory Board currently consists of nine esteemed researchers, clinicians and medical doctors with a body of work in MS and neurorehabilitation that follows the continuum of MS care. The main p

Medical wire that stops the trembling caused by Parkinson’s disease. Precision tools that can manufacture tailored prosthetic limbs durable and flexible enough to race down the slopes.

--Study suggests all cancer patients could benefit from both germline and somatic testing, utility of germline testing in identifying additional treatment options for cancer patients -- [08-October-2020] SAN FRANCISCO , Oct. 8, 2020 /PRNewswire/ -- Tumor-only genetic sequencing misses medically actionable genetic variants in cancer patients that germlin

Clinically meaningful and highly statistically significant results for primary and both key secondary endpoints U.S. Food and Drug Administration grants Fast Track designation to Xywav for idiopathic hypersomnia, a serious sleep disorder with no approved treatment options

Lumen Bioscience , a clinical-stage biopharmaceutical company developing biologic drugs for highly prevalent diseases, today announced the appointment of Mark Litton , PhD, MBA, Chief Operating Officer of Athira Pharma (NASDAQ: ATHA), to the company’s Board of Directors.

IMMUNOPRECISE ANTIBODIES LTD. (the “Company” or “IPA”) (TSXV: IPA) (OTCQB: IPATF) (FSE: TQB2), a leader in full-service, therapeutic antibody discovery and development, today announced an update on their NSERC-funded partnership with the

Potential first-in-class therapy designed to treat the underlying cause of liver disease associated with AATD − Arrowhead is eligible to receive up to $1.04B including an upfront payment of $300M and potential development, regulatory and commercial milestones up to $740M − Investigational medicine ARO-AAT to be co-developed and co-commercialized in the United States by Takeda and Arrowhead under a 50/50 profit-sharing s

Aegle Therapeutics Corporation, a first-in-class biotechnology company developing extracellular vesicles as therapy, today announced that the Company has been awarded a grant by the U.S.

Castle Biosciences, Inc. (Nasdaq: CSTL), a skin cancer diagnostics company providing personalized genomic information to improve cancer treatment decisions, today announced that Medicare Administrative Contractor, Palmetto GBA MolDx, has issued a final expanded local coverage determination (LCD) for the company’s Decisi